Publications by authors named "John Fry"

Claim this Profile
A
A Phase 1 study of the safety, tolerability, and pharmacokinetics of ALG-000184 (pevifoscorvir sodium), a novel Class E capsid assembly modulator, in healthy participants.
Ed Gane, Christian Schwabe, Min Wu, Tse-I Lin, Lawrence Blatt, John Fry

Antivir Ther· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Projecting stock market impacts of climate change via rational bubble models.
John Fry

Risk Anal· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multipart phase 1 study of the safety, pharmacodynamics and pharmacokinetics of ALG-055009, a novel thyroid hormone receptor beta (THR-β) agonist for metabolic dysfunction-associated steatohepatitis (MASH), in healthy participants.
Hakim Charfi, Benedetta Massetto, Megan Fitzgerald, Kha Le, Stanley Wang, John Fry

Clin Pharmacol Drug Dev· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimating lung cancer risk from e-cigarettes and heated tobacco products: applications of a tool based on biomarkers of exposure and of potential harm.
Peter N Lee, Katharine J Coombs, John S Fry

Harm Reduct J· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug Classes.
Marion G Peters, Man-Fung Yuen, Norah Terrault, John Fry, Pietro Lampertico

Clin Infect Dis· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus (RSV) infection: Safety, efficacy, and pharmacokinetic results.
Abbie Oey, Matthew McClure, Julian A Symons, Sushmita Chanda, John Fry

PLoS One· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nomenclature of HBV core protein-targeting antivirals.
Fabien Zoulim, Adam Zlotnick, Stephanie Buchholz, Eric Donaldson, John Fry

Nat Rev Gastroenterol Hepatol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Attention to Authority: The behavioural finance of Covid-19.
Matt Burke, John Fry, Sean Kemp, Drew Woodhouse

Financ Res Lett· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, safety and tolerability of single- and multiple-ascending doses of JNJ-64530440, a novel hepatitis B virus capsid assembly modulator, in healthy volunteers.
Thomas N Kakuda, Jeysen Z Yogaratnam, Christopher Westland, Edward J Gane, Christian Schwabe, John Fry

Antivir Ther· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimating the public health impact had tobacco-free nicotine pouches been introduced into the US in 2000.
Peter N Lee, John S Fry, Tryggve Ljung

BMC Public Health· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimating the reduction in US mortality if cigarettes were largely replaced by e-cigarettes.
Peter N Lee, John S Fry, Stanley Gilliland, Preston Campbell, Andrew R Joyce

Arch Toxicol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cigarette Filter Ventilation and Biomarkers-Letter.
Peter Lee, John Fry

Cancer Epidemiol Biomarkers Prev· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigating the effect of e-cigarette use on quitting smoking in adults aged 25 years or more using the PATH study.
Peter N Lee, John S Fry

F1000Res· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection.
Fabien Zoulim, Oliver Lenz, Joris J Vandenbossche, Willem Talloen, Thierry Verbinnen, John Fry

Gastroenterology· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigating gateway effects using the PATH study.
Peter Lee, John Fry

F1000Res· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Further investigation of gateway effects using the PATH study.
Peter N Lee, John S Fry

F1000Res· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy Subjects.
Joris Vandenbossche, Wolfgang Jessner, Maarten van den Boer, Jeike Biewenga, Jan Martin Berke, John Fry

Adv Ther· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using data on snus use in Sweden to compare different modelling approaches to estimate the population health impact of introducing a smoke-free tobacco product.
Smilja Djurdjevic, Laszlo Pecze, Rolf Weitkunat, Frank Luedicke, John Fry

BMC Public Health· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study on safety and pharmacokinetics of a novel influenza endonuclease inhibitor, AL-794 (JNJ-64155806), following single- and multiple-ascending doses in healthy adults.
Thomas N Kakuda, Jeysen Yogaratnam, Jennifer Rito, Malcolm Boyce, Toni Mitchell, John Fry

Antivir Ther· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects.
Matthew W McClure, Elina Berliba, Tengiz Tsertsvadze, Adrian Streinu-Cercel, Leen Vijgen, John Fry

PLoS One· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Respiratory syncytial virus-A dynamics and the effects of lumicitabine, a nucleoside viral replication inhibitor, in experimentally infected humans.
Kashyap Patel, Carl M Kirkpatrick, Keith A Nieforth, Sushmita Chanda, Qingling Zhang, John Fry

J Antimicrob Chemother· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Updating the evidence relating smoking bans to incidence of heart disease.
Peter N Lee, John S Fry, Alison J Thornton

Regul Toxicol Pharmacol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiviral Activity, Safety, and Pharmacokinetics of AL-794, a Novel Oral Influenza Endonuclease Inhibitor: Results of an Influenza Human Challenge Study.
Jeysen Yogaratnam, Jennifer Rito, Thomas N Kakuda, Hein Fennema, Kusum Gupta, John Fry

J Infect Dis· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short-Duration AL-335, Odalasvir, With or Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without Cirrhosis.
Edward J Gane, Catherine A Stedman, Christian Schwabe, Leen Vijgen, Sushmita Chanda, John Fry

Hepatology· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, safety, and tolerability of the 2- and 3-direct-acting antiviral combination of AL-335, odalasvir, and simeprevir in healthy subjects.
Thomas N Kakuda, Matthew W McClure, Christopher Westland, Jennifer Vuong, Marie-Claude Homery, John Fry

Pharmacol Res Perspect· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis